Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00038090 · ClinicalTrials.gov registry record · Phase 2

Thalidomide-Dexamethasone for Multiple Myeloma

A Phase 2 study of Multiple Myeloma, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 2
Development phase
83
Enrollment target
1
Study location

NCT00038090: Completed Phase 2 study of Multiple Myeloma, sponsored by M.D. Anderson Cancer Center.

NCT00038090 is a Phase 2 study of Multiple Myeloma that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 83 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00038090, a Phase 2 study of Multiple Myeloma, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
83 participants
Enrollment target
1
Study location

Study Summary

Objective is to assess the activity of the combination of thalidomide and dexamethasone in patients with previously untreated multiple myeloma.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Thalidomide

Study Locations (1)

Texas

  • University of Texas M. D. Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 83 participants
Start Date 2000-06
Est. Completion 2005-05
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00038090

The ClinicalTrials.gov registry entry for NCT00038090 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (85% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone is the first listed.

NCT00038090 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00038090 about?

NCT00038090 is a clinical study titled "Thalidomide-Dexamethasone for Multiple Myeloma". Objective is to assess the activity of the combination of thalidomide and dexamethasone in patients with previously untreated multiple myeloma.

What is the current status of trial NCT00038090?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2000-06. Estimated completion is 2005-05.

What conditions does trial NCT00038090 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT00038090?

The interventions under investigation include: Dexamethasone (DRUG), Thalidomide (DRUG).

Who is sponsoring clinical trial NCT00038090?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00038090 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.